Most of the money in the NAD+ space has been bet on muscle, energy and "biological age". So it is worth noting that when researchers pooled the randomised NMN trials in 2026, the one outcome that held up wasn't strength or stamina — it was a couple of millimetres of mercury on a blood pressure cuff. This piece walks through what that 2.15 mmHg actually represents, why the systolic result split by age, and how it sits against Australia's new NMN rules. If you want the background first, our NAD+ compound profile covers the basics.

What the 2026 NMN blood pressure meta-analysis found

Zhang and colleagues, publishing in Nutrients in March 2026, searched PubMed/MEDLINE, Scopus, Web of Science and EBSCO through 13 December 2025 for randomised controlled trials of NMN reporting resting blood pressure in adults with elevated readings. They ended up with 10 RCTs, 11 intervention arms and 349 participants in total.

Pooled against placebo:

  • Diastolic blood pressure fell by 2.15 mmHg (95% CI −3.68 to −0.61) — statistically significant, but small.
  • Systolic blood pressure showed no significant reduction overall.
  • In a subgroup of participants aged 60 and over, systolic fell by 3.94 mmHg (95% CI −7.06 to −0.82).

The authors' own framing is deliberately hedged: preliminary and suggestive evidence, requiring confirmation in long-term, large-scale, high-quality RCTs before NMN could be considered for early-stage blood pressure management.

Why 349 people is the number that matters

Blood pressure meta-analyses in nutrition routinely pool thousands of participants. This one pooled fewer people than a single mid-sized hypertension trial. With 349 participants spread across 11 arms, the confidence interval on the diastolic estimate runs from −3.68 to −0.61 mmHg — the lower bound is close to nothing.

The age-60+ systolic finding is a subgroup analysis, which means it was one of several cuts made by age, BMI, geography, duration, dose and baseline blood pressure. Subgroup results from small pools are hypothesis-generating, not confirmatory. That interval (−7.06 to −0.82) is wide enough to be consistent with either a clinically interesting effect or a trivial one.

There is also a practical ceiling on what any of this means for an individual. A 2 mmHg shift is well inside the ordinary variation between two readings on the same arm on the same morning. It's a population-level average, not something a person can feel or verify at home.

A second 2026 pooling reached the same partial conclusion

A separate systematic review and meta-analysis, also in Nutrients in 2026, looked at safety and metabolism-related outcomes of oral NMN. Its findings were largely null: no significant effects on body weight, BMI, fasting glucose, HbA1c, lipid profiles or systolic blood pressure. Short-term tolerability looked favourable, with no clear increase in adverse events or liver biochemistry abnormalities.

But it reported the same directional finding — a slight decrease in diastolic blood pressure, plus a non-significant downward trend in HOMA-IR — and described these as preliminary vascular-metabolic signals, particularly in older adults or those with early metabolic risk.

Two independent teams landing on the same signal sounds like replication. It mostly isn't. Both were drawing from the same small pool of published NMN RCTs, so the overlap in included studies is substantial. What you have is two reasonable readings of one modest evidence base, not two separate confirmations.

The muscle hypothesis didn't survive the same treatment

The contrast is instructive. Prokopidis and colleagues published a systematic review and meta-analysis in the Journal of Cachexia, Sarcopenia and Muscle in 2025 covering 10 RCTs of NMN (six trials) or NR (four trials) in adults with mean ages from 60.9 to 83, at doses of 250–2000 mg/day for 3 to 24 weeks.

The pooled result: no significant effect on skeletal muscle index, handgrip strength, gait speed or the five-times chair-stand test. Their conclusion was that current evidence does not support NMN or NR for preserving muscle mass and function in this age group, and that future work should address dosing, baseline NAD+ deficiency and combination interventions.

That matters because sarcopenia and "energy" are the two things NAD+ precursors are most often sold on. The mechanistic story — raise NAD+, restore mitochondrial function, improve muscle — is coherent. It just hasn't shown up in pooled human function outcomes yet. Meanwhile, the endpoint nobody was marketing has produced the more consistent signal. That ordering is worth sitting with before treating any NAD+ precursor as a performance intervention. For how this pattern repeats elsewhere, see our wider peptides and compounds index.

Is NMN legal in Australia? The TGA position in 2026

Australia's regulatory picture changed on 10 December 2025, when NMN was added to the Therapeutic Goods (Permissible Ingredients) Determination. The conditions are specific:

  • Oral route only, as an active ingredient.
  • Maximum recommended daily dose of 500 mg of nicotinamide mononucleotide.
  • A sponsor-exclusivity arrangement running to 10 December 2027, under which NMN can only be used where SyncoZymes (Shanghai) Co Ltd is the sponsor, or a secondary sponsor has been authorised and the TGA notified.

Two details are easy to miss. First, NAD+ and NADH themselves remain non-permitted ingredients in Australian listed medicines — the TGA has published safety advice about NAD, NAD+, NADH and NMN products sold locally. Nicotinamide riboside (NR) is permitted; NAD+ itself is not, in any listed oral form. Second, intravenous NAD+ infusions, widely marketed through wellness clinics, have very little published clinical evidence behind them, and nothing in the 2026 meta-analyses speaks to them at all.

There's also an alignment question. The pooled trials ran at 250–2000 mg/day for 3–24 weeks. Australia's permitted envelope caps out at 500 mg/day and is intended for short-term use of up to 12 weeks. So the lower-dose, shorter-duration end of that literature is the part that maps onto what can lawfully be sold here — which is another reason to treat extrapolations from higher-dose trials cautiously.

Internationally, the FDA reversed its exclusion of NMN from the dietary supplement category in September 2025, which is part of why the regulatory conversation moved quickly through late 2025.

What a reasonable reading looks like

The honest summary: NMN reliably raises circulating NAD+, appears well tolerated in short trials, and has produced a small, consistent diastolic blood pressure signal across two 2026 poolings of a shared, small evidence base. It has not shown muscle or functional benefit when pooled. Nothing here establishes that NMN reduces cardiovascular events, because no trial has been designed or powered to test that.

If you're tracking whether the age-60+ systolic subgroup survives a properly powered trial, join the free updates list — that's the result worth waiting for.

FAQ

Does NMN lower blood pressure?

A 2026 meta-analysis of 10 RCTs and 349 participants found a small but statistically significant 2.15 mmHg reduction in diastolic blood pressure versus placebo, with no significant systolic effect overall. The authors described the evidence as preliminary and called for larger, longer trials.

Is NMN legal in Australia?

Yes, with conditions. The TGA added NMN as a permitted ingredient on 10 December 2025 for oral listed medicines at a maximum of 500 mg per day, with sponsor exclusivity until December 2027. NAD+ and NADH themselves remain non-permitted ingredients in Australia.

Does NMN or NR build muscle in older adults?

Not on current pooled evidence. A 2025 meta-analysis of 10 RCTs in adults averaging 60.9–83 years found no significant effect of NMN or NR on skeletal muscle index, handgrip strength, gait speed or chair-stand performance.

Is NAD+ a peptide?

No. NAD+ is a coenzyme — a nucleotide-based molecule involved in cellular energy metabolism — not a peptide. It's often grouped with peptides in the longevity market, but it belongs to a different chemical class entirely.

Sources

This article is independent editorial information, not medical advice. NAD+ is a coenzyme, not a peptide; oral NMN is a TGA-permitted listed medicine ingredient in Australia under dose and sponsor conditions, while NAD+ and NADH are not permitted ingredients, and intravenous NAD+ is not an approved therapy. Speak with a qualified Australian health professional before making any health decision.